Q&A: Navigating Proactive, Reactive TDM in a Private Practice Setting

Differentiating patients with inflammatory bowel disease who have lost response to a biologic used to be considered a “gray zone,” according to Sushama Gundlapalli, MD, MS, a board-certified gastroenterologist at Suburban Gastroenterology Ltd. in Naperville, Illinois.But, according to Gundlapalli, the introduction of therapeutic drug monitoring (TDM) has helped clarify a patient’s clinical picture as being a mechanistic or pharmacokinetic failure, guiding us to direct therapies in a more targeted way.“We have been steadily increasing our reactive drug monitoring in theRead More

Share on facebook
Share on twitter
Share on linkedin